Corrigendum to "Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study" [Eur. J. Cancer 2025 Aug 26;226:115535. PMID: 40743655] Eur J Cancer
Impact of MICA-129 mismatch on HSCT outcomes: Evidence from a large European cohort and meta-analysis TRANSPL CELL THER
Variations in Innate Immune Cell Subtypes Correlate with Epigenetic Clocks, Inflammaging and Health Outcomes ADV SCI
The impact of cancer survivors' extra risk of non-cancer mortality on net survival estimation Am J Epidemiol
Standard Versus Reduced-Doses of Post-Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation Eur J Haematol
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study BRIT J HAEMATOL
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial Lancet Haematol
Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica